Biopharma Dealmakers A supplement to Nature Biotechnology and Nature Reviews Drug Discovery
Check out the latest issue of Biopharma Dealmakers, which includes the following features: - Diseases related to the immune system touch off a spectrum of valuable business models - Oncology patent cliff makes way for younger biotechs
SciBX: Science-Business eXchange Collection on Antibiotic Resistance
This special Collection from SciBX: Science-Business eXchange provides an overview of the state of affairs on antibiotic resistance from the scientific, business and regulatory perspectives.
Building meditope-enabled mAbs Kai-Jye Lou doi:10.1038/scibx.2013.1178 Researchers at the Beckman Research Institute at City of Hope have provided proof of concept for adapting the functionality of mAbs by modifying them with engineered peptides called meditopes. The institute founded Meditope Biosciences to commercialize the technology. Full Text | PDF
KCC2 escape from neuropathic pain Benjamin Boettner doi:10.1038/scibx.2013.1179 Researchers from Laval University have described an activator of the co-transporter KCC2 and shown its analgesic effect in mice. The group is developing next-generation compounds with better pharmacological properties. Full Text | PDF
Benztropine for MS Lauren Martz doi:10.1038/scibx.2013.1180 Although candidate compounds to treat secondary progressive multiple sclerosis abound, few lead to neuronal remyelination. A new study has suggested that an existing Parkinson's disease drug—benztropine—or a derivative could accomplish the task. Full Text | PDF
Personal factors Chris Cain doi:10.1038/scibx.2013.1181 A multi-institute team collaborating with the FDA has determined why patients with a form of severe hemophilia rarely develop neutralizing antibodies against factor VIII replacement therapy. The group is developing an algorithm to predict the likelihood of antibody development against other recombinant protein–based therapies. Full Text | PDF
Colony-stimulating factor 1 receptor (CSF1R; C-FMS; CD115) doi:10.1038/scibx.2013.1182 Mouse studies suggest the brain-penetrant CSF1R inhibitor BLZ945 could be used to treat glioblastoma multiforme (GBM). Full Text | PDF
CD3; folate receptor doi:10.1038/scibx.2013.1183 In vitro and mouse studies suggest an anti-CD3 antibody conjugated to folic acid could help treat cancer. Full Text | PDF
Ribonucleotide reductase M2 (RRM2; R2) doi:10.1038/scibx.2013.1184 Cell culture and mouse studies identified RRM2 inhibitors that could help treat drug-resistant cancers. Full Text | PDF
Tubulin doi:10.1038/scibx.2013.1185 In vitro and mouse studies suggest azaindole-based tubulin inhibitors could help treat cancer. Full Text | PDF
Carbonic anhydrase XII (CAXII) doi:10.1038/scibx.2013.1186 Cell culture and mouse studies identified an anti-CAXII mAb that could help treat cancer. Full Text | PDF
Second chromosome locus associated with prostate-1 (SChLAP1; LINC00913) doi:10.1038/scibx.2013.1187 Cell culture and mouse studies suggest inhibiting the long noncoding RNA (lncRNA) SChLAP1 could help treat prostate cancer. Full Text | PDF
Unknown doi:10.1038/scibx.2013.1188 Computational, cell culture and mouse studies identified marketed drugs that could be repurposed to treat SCLC. Full Text | PDF
Myocardin-related transcription factor A (MKL1; MAL; MRTF-A) doi:10.1038/scibx.2013.1190 Mouse studies suggest MRTF-A activation could help treat dermal wounds. Full Text | PDF
CD4 doi:10.1038/scibx.2013.1191 In vitro studies suggest addition of an N-linked glycan to the anti-CD4 mAb ibalizumab could help improve its ability to neutralize HIV-1 strains that are resistant to the antibody. Full Text | PDF
Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) doi:10.1038/scibx.2013.1192 Mouse and in vitro studies identified dihydrothiophenone-derived inhibitors of PfDHODH that could be useful for treating malaria. Full Text | PDF
Calcium channel voltage-dependent α2/δ subunit 2 (CACNA2D2) doi:10.1038/scibx.2013.1193 In vitro and mouse studies suggest voltage-gated calcium channel inhibitors could help treat or prevent New World hemorrhagic fever triggered by arenaviruses. Full Text | PDF
Not applicable doi:10.1038/scibx.2013.1194 In vitro and rat studies identified nitroxyl (HNO)-donating aspirin derivatives that could help treat inflammation. Full Text | PDF
Adenylate cyclase-stimulating Gα protein (GNAS); glioma-associated oncogene homolog 1 zinc finger protein (GLI1) doi:10.1038/scibx.2013.1195 In vitro and mouse studies suggest hedgehog pathway inhibitors could help treat heterotopic ossification caused by loss-of-function GNAS mutations. Full Text | PDF
Microtubule-associated protein-τ (MAPT; TAU; FTDP-17) doi:10.1038/scibx.2013.1196 Cell culture and mouse studies identified anti-TAU mAbs that could be useful for treating AD. Full Text | PDF
Endonuclease G (ENDOG) doi:10.1038/scibx.2013.1197 In vitro and in vivo studies suggest inhibiting ENDOG could help treat PD. Full Text | PDF
Hemopexin (HPX); toll-like receptor 4 (TLR4) doi:10.1038/scibx.2013.1198 Mouse studies suggest TLR4 blockade or recombinant HPX could help prevent SCD-associated acute chest syndrome. Full Text | PDF
Additional sex combs like 1 (Asxl1)-mutant mouse model of myelodysplastic syndrome (MDS) doi:10.1038/scibx.2013.1199 Mice transplanted with bone marrow expressing a mutant form of Asxl1 could model MDS and be used to identify and evaluate new treatments for the condition. Full Text | PDF
Methyl CpG binding protein 2 (MECP2; RTT)-deficient neurons derived from human embryonic stem cells (hESCs) doi:10.1038/scibx.2013.1200 MECP2-deficient neurons derived from hESCs could be useful for studying Rett syndrome and screening for therapeutics to treat the disease. Full Text | PDF
Transgenic mouse model of early α-synuclein (SNCA) overexpression in Parkinson's disease (PD) doi:10.1038/scibx.2013.1201 An SNCA-overexpressing transgenic mouse PD model could help define early defects in dopaminergic neurons and help evaluate candidate therapeutic strategies. Full Text | PDF
DNA nanostructures for targeted drug delivery doi:10.1038/scibx.2013.1202 Nanostructures generated via unconventional assembly of DNA could enable targeted drug delivery or be used as imaging agents. Full Text | PDF
Functionalizing mAbs with a noncovalent peptide-binding site doi:10.1038/scibx.2013.1203 A peptide-binding site found on Erbitux cetuximab could be used to functionalize mAbs without disrupting their native antigen-binding properties. Full Text | PDF
Image-based high-content screening platform to survey large compound libraries doi:10.1038/scibx.2013.1204 A platform combining chemical screening with automated image acquisition and analysis could enable the identification of compounds that inhibit disease-associated signal transduction pathways. Full Text | PDF
Intramyocardial injection of synthetic modified RNA (modRNA) encoding VEGF-A to expand and direct differentiation of cardiac progenitor cells doi:10.1038/scibx.2013.1205 Mouse studies suggest pulse-like expression of VEGF-A from modRNA could help regenerate cardiac tissue. Full Text | PDF
Reprogramming in vivo to generate totipotent induced pluripotent stem (iPS) cells doi:10.1038/scibx.2013.1206 In vivo reprogramming in mice could be used to generate highly plastic iPS cells that can efficiently contribute to extraembryonic tissue such as placenta. Full Text | PDF
Toll-like receptor 9 (TLR9) or TLR3 adjuvants to promote cancer vaccine–induced effector T cell expansion doi:10.1038/scibx.2013.1207 Mouse studies suggest TLR9 or TLR3 ligands can enhance cancer vaccine–induced effector T cell expansion. Full Text | PDF
Copper complex–based imaging agents to diagnose Alzheimer's disease (AD) doi:10.1038/scibx.2013.1208 Studies in mice and human samples suggest copper complex–based imaging agents could help diagnose AD. Full Text | PDF
Gene expression signature to predict outcome in patients with idiopathic pulmonary fibrosis (IPF) doi:10.1038/scibx.2013.1209 Studies in patient samples identified a gene expression signature that could help predict outcomes in patients with IPF. Full Text | PDF
Nature Publishing Group and Relay Technology Management present: The Epigenetics Target Explorer
Click here to access this free online tool and the accompanying article in Nature Reviews Drug Discovery.
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant)
Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA
Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston
Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.
No comments:
Post a Comment